摘要
摘要
Recently published in The Lancet, CheckMate 9DW evaluated the efficacy and safety of dual immune checkpoint blockade nivolumab plus ipilimumab (Nivo/Ipi) compared to either sorafenib or lenvatinib in treatment-naive patients with unresectable hepatocellular carcinoma. This open-label, randomized phase 3 trial demonstrated that Nivo/Ipi provides an overall survival benefit versus lenvatinib or sorafenib.1.
KM 提取结果
0 个 Figure · 0 个 KM 面板